Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026)
Pelthos Therapeutics (PTHS) posted Gross Margin of 80.07% for Q2 2026, down 5.42% on a QoQ basis from 84.66% in Q1 2026.
Powered by 
Analysis
Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026) Analysis & Trends
Pelthos Therapeutics has reported Gross Margin for 2 years, with the latest figure at 80.07% in Q2 2026.
- On a quarterly basis, Gross Margin changed N/A year-over-year to 80.07% in Q2 2026; TTM through Jun 2026 was 79.7%, a N/A change from a year earlier, with the FY2025 full-year figure at 76.25%, changed N/A from the prior year.
- Gross Margin was 80.07% for Q2 2026 at Pelthos Therapeutics, down from 84.66% in the prior quarter.
- The five-year high for Gross Margin was 84.66% in Q1 2026, with the low at 68.73% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.02 Bn | 620.27 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 445.75 Bn | 439.18 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 357.52 Bn | 350.38 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 267.31 Bn | 259.62 Bn | 11.24 Bn | 78.02% |
| 5 | Pfizer | 156.58 Bn | 144.88 Bn | 10.94 Bn | 72.78% |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | 80.05% |
| 7 | Revolution Medicines | 43.04 Bn | 43.04 Bn | - | - |
| 8 | Incyte | 24.61 Bn | 20.07 Bn | 1.57 Bn | 93.73% |
| 9 | United Therapeutics | 21.30 Bn | 18.64 Bn | 683.80 Mn | 87.30% |
| 10 | Pelthos Therapeutics | 80.28 Mn | 55.72 Mn | 21.23 Mn | 80.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80.07% |
| Mar 31, 2026 | 84.66% |
| Dec 31, 2025 | 81.61% |
| Sep 30, 2025 | 68.73% |